Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvele Tablets, 800 mg, of Genzyme
Corporation.
Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Sevelamer Carbonate Tablets (RLD: Renvele) had estimated annual sales of USD 348 million in the U.S. (IQVIA MAT September 2020).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
